Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

ABRYSVO™: Pfizer Canada's Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults Français

Pfizer Canada (CNW Group/Pfizer Canada)

News provided by

Pfizer Canada

Sep 19, 2024, 07:00 ET

Share this article

Share toX

Share this article

Share toX

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025. ABRYSVO™ is approved by Health Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older.i ABRYSVO™ is also the only RSV vaccine authorized for the prevention of RSV in infants via immunization of pregnant individuals.ii RSV is a contagious respiratory virus that disproportionately impacts older adults, especially those who have underlying medical conditions, weakened immune systems or those living in long-term care.iii

As part of their commitment to protecting the health of older adults in Canada, several provinces and territories are introducing ABRYSVO™ to their publicly funded immunization programs, granting access to ABRYSVO™ free of charge for those who are eligible. Pfizer Canada commends the provinces and territories for their responsiveness to fill an unmet medical need within months following the approval of ABRYSVO™ by Health Canada.

The decision comes after a strong recommendation was issued by the National Advisory Committee on Immunization (NACI) in July 2024. NACI recommends RSV immunization programs for adults 75 years of age and older, particularly for those who are at increased risk of severe RSV disease or adults 60 years of age and older who are residents of nursing homes and other chronic care facilities.iv Those who fall into these groups are encouraged to check their province's publicly funded immunization schedules for eligibility criteria specifics.

"Older adults are among the most vulnerable to contracting RSV and experiencing serious complications that diminish function and quality of life. Vaccination is a key prevention strategy to protect against RSV and reduce the incidence and impact of this disease in older people," said Ms. Katrina Bouzanis, Director of Policy, Advocacy and Innovation at the International Federation on Ageing (IFA). "The IFA hopes that all Canadian provinces and territories will support access to RSV vaccination by adding it to their public health coverage programs."

While RSV usually causes mild, cold-like symptoms, pre-existing medical conditions that commonly impact older adults, such as chronic heart disease and diabetes, can increase the risk of severe RSV. Older adults are also more susceptible to lower respiratory tract infection complications from RSV, such as pneumonia.v, vi

"Vaccination is one of the most effective tools to help protect against vaccine-preventable diseases such as RSVvii," said Dr. Vivien Brown, a Toronto-based Family Physician. "Having Canadian health authorities step in to address the burden of preventable RSV-related hospitalizations is a notable way to support not only the health of high-risk individuals, but also the state of Canada's healthcare system."

In Canada, older adults have the highest mortality rate attributed to RSV infections, representing over 80 per cent of deaths caused by the disease each year.viii, ix  RSV-related hospitalization is also the highest among older adults with those who live in long-term care having longer hospital stays than the general population due to RSV.x, xi

"The NACI recommendation acknowledges how RSV immunization with ABRYSVO™ can help ease the impact of RSV among older adults and Canada's healthcare system," said Pfizer Canada's Access & Value Vice President, Karine Grand'Maison "Pfizer Canada is committed to supporting the health of Canadian families by ensuring access to vaccines; by proactively protecting the health of older adults, we are supporting the health of every community."

About ABRYSVO™

ABRYSVO™ was approved in December 2023 by Health Canada for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV. The vaccine is indicated for active immunization of individuals 60 years of age and older. ABRYSVO™ is the only RSV vaccine authorized in Canada for active immunization of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory disease in infants from birth through six months of age.xii

About Pfizer Canada

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. At Pfizer, we apply science and our global resources to bring therapies to people that help extend and improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, X, Instagram or YouTube.

_______________________________________________
i Government of Canada. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Accessed August 2024 at https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html
ii Product Monograph. ABRYSVO. Accessed August 2024 at https://pdf.hres.ca/dpd_pm/00073900.PDF
iii Mayo Clinic. Respiratory syncytial virus (RSV). Accessed August 2024 at https://www.mayoclinic.org/diseases-conditions/respiratory-syncytial-virus/symptoms-causes/syc-20353098
iv Government of Canada. Summary of NACI statement of July 12, 2024: Statement on the prevention of respiratory syncytial virus disease in older adults. Accessed August 2024 at www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-statement-prevention-rsv-disease-older-adults.html
v RSV and Me. Being an older adult can put you at risk for serious complications due to respiratory syncytial virus (RSV). Accessed August 2024 at https://www.rsvandme.ca/en-ca/rsv-and-older-adults/#:~:text=Being%20an%20older%20adult%20can,off%20viruses%20such%20as%20RSV.
vi Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. Accessed August 2024 at https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html
vii Government of Canada. The facts about COVID-19 vaccines. Accessed August 2024 at https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/awareness-resources/know-vaccine.html
viii Global News. RSV vaccine for older Canadians comes at a cost. Why experts are worried. Accessed August 2024 at https://globalnews.ca/news/10001009/rsv-vaccine-cost-older-canadians-cost/.
ix National Institute on Ageing. Why Are So Many People Dying of a Preventable Disease in Canada. Accessed August 2024 at https://www.niageing.ca/commentary-posts/why-are-so-many-canadians-dying-preventable-disease
x Ontario Ministry of Health. Respiratory Syncytial Virus (RSV) Fact Sheet for Long-Term Care, Elder Care Lodges and Retirement Homes. Accessed August 2024 at https://files.ontario.ca/moh-respiratory-syncytial-virus-fact-sheet-for-health-care-providers-en-2023-11-10.pdf
xi Government of Canada. Respiratory syncytial virus (RSV): For health professionals. Accessed August 2024 at https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html
xii Product Monograph. ABRYSVO. Accessed August 2024 at https://pdf.hres.ca/dpd_pm/00073900.PDF

SOURCE Pfizer Canada

Media Inquiries: Corporate Affairs Canada, 1-866-9PFIZER (1-866-973-4937), [email protected]

Modal title

Organization Profile

Pfizer Canada

    Also from this source

  • Pfizer Canada and partners announce quality improvement grant recipients for Canada's most prevalent cancers

  • An Van Gerven Is Appointed President of Pfizer Canada

  • Pfizer Canada and the Skin Spectrum Summit Announce 2024 Recipients of the Canadian Skin of Colour & Diversity Scholarship

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.